IP Library › Granted Patent US 12,377,072
Granted Patent B2
US 12,377,072 · App. 18/138,306 · Granted Aug 5, 2025

Modulators of GTPases and their use

Inventors: Angela Wandinger-Ness (Albuquerque, NM); Laurie Hudson (Albuquerque, NM); Larry Sklar (Albuquerque, NM); Zurab Surviladze (Albuquerque, NM); Tudor Oprea (Albuquerque, NM)
Assignee: UNM Rainforest Innovations
A61K31/407A61K31/403A61K31/415A61K45/06C07D231/06C12Q1/6886G01N33/573C12Q2600/106C12Q2600/158Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,072
App. No.
18/138,306
Granted
Aug 5, 2025
Kind
B2
Abstract

The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.

Claims (8)

1. A method of modulating GTPase in a human patient with ovarian cancer, the method comprising administering to said patient an anti-cancer effective amount of a composition comprising ketorolac, or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, additive or excipient, wherein the ketorolac consists of an effective amount of R-ketorolac.

2. The method of claim 1 , wherein the cancer is metastatic.

3. The method of claim 1 , wherein the cancer is recurrent.

4. The method of claim 1 , wherein the composition is in parenteral dosage form.

5. The method of claim 1 , wherein the composition is in oral dosage form.

6. The method of claim 1 , wherein said composition is co-administered with an additional anti-cancer agent.

7. The method of claim 6 , wherein the additional anti-cancer agent is selected from the group consisting of gemcitabine, doxorubicin, liposomal doxorubicin, capecitabine, tamoxifen, carboplatin, cisplatin, epirubicin, gemcitabine, oxaliplatin, valrubicin, vinorelbine, trastuzumab, paclitaxel, cremophor-free paclitaxel, docetaxel and mixtures thereof.

8. The method of claim 6 , wherein the additional anti-cancer agent is carboplatin, cisplatin, docetaxel, paclitaxel or a mixture thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2026
From: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO
To: UNM RAINFOREST INNOVATIONS
Reel/Frame 074854/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2026
From: WANDINGER-NESS, ANGELA; SURVILADZE, ZURAB; SKLAR, LARRY A.; HUDSON, LAURIE; OPERA, TUDOR I.
To: THE REGENTS OF THE UNIVERSITY OF NEW MEXICO
Reel/Frame 074854/0186 →
Continuity (6)
Continuation 17095399 · Nov 11, 2020
Continuation 15445413 · Feb 28, 2017
Continuation 14813874 · Jul 30, 2015
Continuation 13161766 · Jun 16, 2011
Provisional Application 61397864 · Jun 17, 2010
Related Publication 20230404977A1 · Dec 21, 2023
References Cited (12)
US 10391080B2 · Malhotra et al. · 2019 [cited by applicant]
“U.S. Appl. No. 17/095,399, Non Final Office Action mailed Apr. 26, 2022”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 17/095,399, Notice of Allowance mailed Jan. 23, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/095,399, Preliminary Amendment filed Apr. 5, 2021”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/095,399, Response filed Apr. 15, 2022 to Restriction Requirement mailed Feb. 15, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/095,399, Response filed Sep. 26, 2022 to Non Final Office Action mailed Apr. 26, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 17/095,399, Restriction Requirement mailed Feb. 15, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 17/095,399, Supplemental Amendment filed Jan. 3, 2023”, 2 pgs. [cited by applicant]
U.S. Appl. No. 13/161,766 U.S. Pat. No. 9,125,899, filed Jun. 16, 2011, Modulators of GTPases and Their Use. [cited by applicant]
U.S. Appl. No. 14/813,874, filed Jul. 30, 2015, Modulators of GTPases and Their Use. [cited by applicant]
U.S. Appl. No. 15/445,413 U.S. Pat. No. 10,857,130, filed Feb. 28, 2017, Modulators of GTPases and Their Use. [cited by applicant]
U.S. Appl. No. 17/095,399 U.S. Pat. No. 11,672,779, filed Nov. 11, 2020, Modulators of GTPases and Their Use. [cited by applicant]